Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating

Maze Therapeutics (NASDAQ:MAZE) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities research analysts have also recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. HC Wainwright lifted their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Truist Financial assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $68.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $64.11.

Maze Therapeutics Trading Down 4.2%

Shares of MAZE opened at $30.38 on Friday. The stock has a market capitalization of $1.51 billion, a P/E ratio of -9.41 and a beta of 4.47. The firm’s fifty day simple moving average is $45.61 and its two-hundred day simple moving average is $37.62. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Insider Buying and Selling

In other news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at $426,001.68. This represents a 87.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Amy Bachrodt sold 10,000 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $526,119.70. This represents a 43.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 245,000 shares of company stock valued at $10,504,792.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. increased its position in shares of Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after purchasing an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. increased its holdings in Maze Therapeutics by 27.1% during the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after purchasing an additional 362,060 shares in the last quarter. Woodline Partners LP raised its stake in shares of Maze Therapeutics by 10.0% in the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Maze Therapeutics by 9.0% in the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after purchasing an additional 69,771 shares in the last quarter.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
• Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
• Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
• Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
• Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.